Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HoyaHOCPY +2.72%98 3-Year ROIIC % is 115.11 as of Mar. 2026, which is 79% above its 10-year median of 64.30. GuruFocus rates HOCPY with a GF Score™ of 98/100 and a GF Value™ of $149.62 (Fairly Valued). The stock has 1 warning sign investors should review. Among 796 Medical Devices & Instruments companies, Hoya ranks better than 89.95% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Hoya's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 115.11%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Hoya's 3-Year ROIIC % or its related term are showing as below:
HOCPY's 3-Year ROIIC % is ranked better than 89.95% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs HOCPY: 115.11
Hoya (OTCPK:HOCPY) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Hoya 3-Year ROIIC % Related Terms
Hoya 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Hoya's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOCPY vs ISRG, BDX, MDLN: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Hoya's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hoya 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hoya's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Hoya's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Hoya (HOCPY) has a 3-Year ROIIC % of 115.11 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hoya and its competitors. This is 79% above median its historical median of 64.30. According to the industry distribution chart, Hoya ranks #80 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 10.1%.
Is Hoya's 3-Year ROIIC % too high?
Hoya's current 3-Year ROIIC % of 115.11 is 79% above median its 10-year median of 64.30. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.62. Hoya's value of 115.11 is 7005.6% above this industry median. Based on the distribution chart, Hoya ranks #80 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Hoya has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hoya's 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Hoya ranks #80 out of 796 companies for 3-Year ROIIC %. This places Hoya in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.62. Hoya's value of 115.11 is 7005.6% above this benchmark. While the company's 10-year median is 64.30 vs. the industry median of 1.62, Hoya has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hoya's current 3-Year ROIIC % of 115.11 is 7005.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hoya and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hoya's current 3-Year ROIIC % is 115.11, which is 79% above median its own 10-year median of 64.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hoya stock overvalued right now?
Based on GuruFocus' analysis, Hoya (HOCPY) is currently considered Fairly Valued. The stock's GF Value™ is $149.62, compared to a current price of $157.11 — trading 5% above its estimated fair value. The current 3-Year ROIIC % is 115.11, which is 79% above median its 10-year median of 64.30 and 7005.6% above the Medical Devices & Instruments industry median of 1.62. Hoya's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Hoya (HOCPY), the current 3-Year ROIIC % is 115.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hoya (HOCPY) Overvalued in 2026?
Based on GuruFocus' analysis, Hoya stock appears to be overvalued.
The current stock price of $157.11 is trading 5% above its estimated GF Value™ of $149.62.
GuruFocus considers Hoya to be Fairly Valued.
Key valuation signals for HOCPY:
3-Year ROIIC %: 115.11 (79% above median its 10-year median of 64.30)
GF Value™: $149.62 vs. price of $157.11 (5% above fair value)
Industry Position: 7005.6% above the Medical Devices & Instruments median (#80 of 796)
No single metric tells the full story. See the HOCPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 1941 in Tokyo as an optical glass production plant, Hoya is one of the largest eyeglass lens manufacturers in the world. Leveraging its technology know-how in glass manufacturing, Hoya entered the mask blanks business in 1974. Now although its life care business accounts for more than 60% of its total revenue, majority of its profit before tax comes from its higher-margin IT business.
98GF Score
Get the complete analysis for HOCPY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOCPY has been successfully added to your 
